Cargando…

Intestinal permeability in patients with IgA nephropathy and other glomerular diseases: an observational study

BACKGROUND: A dysregulated ‘gut-kidney axis’ may contribute to immunoglobulin A nephropathy (IgAN). We studied whether IgAN patients have disturbed intestinal permeability. METHODS: In a prospective, cross sectional, pilot study we assessed intestinal permeability in 35 IgAN patients, 18 patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Seikrit, Claudia, Schimpf, Judith I., Wied, Stephanie, Stamellou, Eleni, Izcue, Ana, Pabst, Oliver, Rauen, Thomas, Lenaerts, Kaatje, Floege, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998562/
https://www.ncbi.nlm.nih.gov/pubmed/36107369
http://dx.doi.org/10.1007/s40620-022-01454-2
Descripción
Sumario:BACKGROUND: A dysregulated ‘gut-kidney axis’ may contribute to immunoglobulin A nephropathy (IgAN). We studied whether IgAN patients have disturbed intestinal permeability. METHODS: In a prospective, cross sectional, pilot study we assessed intestinal permeability in 35 IgAN patients, 18 patients with non-IgAN glomerulonephritides (GNs) and 19 healthy controls. After an overnight fast, trial participants ingested a multi-sugar solution and samples were obtained from 0 to 2, 2 to 5- and 5 to 24-h urine portions. Urinary sugar concentrations were quantified using isocratic ion-exchange high performance liquid chromatography. Indices of small intestinal permeability (0–2-h lactulose/L-rhamnose (L/R) ratio), distal small intestinal and proximal colonic permeability (2–5-h sucralose/erythritol (S/E) ratio) and colonic permeability (5–24-h sucralose/erythritol (S/E) ratio) were evaluated. Associations between groups and indices of intestinal permeability were investigated by a linear mixed model. RESULTS: Small intestinal permeability (0–2 h L/R-ratio) was significantly increased in patients with glomerular diseases versus healthy controls. More precisely, increased small intestinal permeability was exclusively noted in non-IgAN GN patients, whereas IgAN patients exhibited a trend towards elevated small intestinal permeability. In total, 54% of patients with IgAN and 67% of non-IgAN GN patients had increased small intestinal permeability. Neither distal small intestinal and proximal colonic permeability nor colonic gut permeability indices (i.e., 2–5 h and 5–24 h S/E ratios) were significantly different between controls and any of the GN patient groups. CONCLUSION: The present single center pilot study suggests that disturbed intestinal permeability is common in patients with glomerular diseases and is not specific for IgAN. TRIAL REGISTRATION NUMBER: German Clinical Trials Register DRKS00021533, Date: 24.04.2020. GRAPHICAL ABSTRACT: [Image: see text]